Ohio State University Comprehensive Cancer Center
🇺🇸United States
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Phase 2
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- Radiation: Intensity-Modulated Radiation Therapy (IMRT) External Beam RadiationProcedure: Triple endoscopy and biopsy
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2021-11-26
- Target Recruit Count
- 11
- Registration Number
- NCT00566540
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Phase 1
Completed
- Conditions
- LymphomaSmall Intestine Cancer
- Interventions
- Other: Correlative studies
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2015-07-16
- Target Recruit Count
- 23
- Registration Number
- NCT00561418
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors
Not Applicable
Completed
- Conditions
- Breast CancerDepressionFatiguePain
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2014-05-05
- Target Recruit Count
- 200
- Registration Number
- NCT00486525
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2017-04-04
- Target Recruit Count
- 49
- Registration Number
- NCT00456872
- Locations
- 🇺🇸
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2017-02-20
- Target Recruit Count
- 17
- Registration Number
- NCT00418496
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Phase 1
Completed
- Conditions
- Brain TumorBrain Metastases
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-06-01
- Target Recruit Count
- 17
- Registration Number
- NCT00362817
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Phase 2
Completed
- Conditions
- Anaplastic OligodendrogliomaOligoastrocytoma, Mixed
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-11-30
- Target Recruit Count
- 1
- Registration Number
- NCT00362570
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Phase 1
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2017-01-20
- Target Recruit Count
- 24
- Registration Number
- NCT00323323
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Phase 2
Withdrawn
- Conditions
- Renal Cancer
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 5
- Registration Number
- NCT00293579
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States